ArticleBiomedicines2023
In Silico, In Vitro, and Ex Vivo Biological Activity of Some Novel Mebeverine Precursors.
Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Correction: Milusheva et al. In Silico, In Vitro, and Ex Vivo Biological Activity of Some Novel Mebeverine Precursors.Biomedicines · 2025Article
- Functionalized Silver Nanoparticles as Multifunctional Agents Against Gut Microbiota Imbalance and Inflammation.Nanomaterials (Basel, Switzerland) · 2025Article
- Synthesis, Cytotoxic and Genotoxic Evaluation of Drug-Loaded Silver Nanoparticles with Mebeverine and Its Analog.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Spasmolytic Activity and Anti-Inflammatory Effect of Novel Mebeverine Derivatives.Biomedicines · 2024Article
- Therapeutic Potential of 1-(2-Chlorophenyl)-6,7-dimethoxy-3-methyl-3,4-dihydroisoquinoline.Molecules (Basel, Switzerland) · 2024Article
- Spasmolytic Activity of 1,3-Disubstituted 3,4-Dihydroisoquinolines.Biomedicines · 2024Article
- Antileishmanial Effect of 1,5- and 1,8-Substituted Fused Naphthyridines.Molecules (Basel, Switzerland) · 2023Article
- Synthesis, Molecular Docking, and Biological Evaluation of Novel Anthranilic Acid Hybrid and Its Diamides as Antispasmodics.International journal of molecular sciences · 2023Article
- Drug-Loaded Silver Nanoparticles-A Tool for Delivery of a Mebeverine Precursor in Inflammatory Bowel Diseases Treatment.Biomedicines · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is a functional gastroenterological disorder with complex pathogenesis and multifaceted therapy approaches, aimed at alleviating clinical symptoms and improving the life quality of patients. Its treatment includes dietary changes and drugs from various pharmacological groups such as antidiarrheals, anticholinergics, serotonin receptor antagonists, targeting chloride ion channels, etc. The present article is focused on the synthesis and biological evaluation of some mebeverine precursors as potential antispasmodics.
methodsIn silico analysis aimed at predicting the pharmacodynamic profile of the compounds was performed. Based on these predictions, ex vivo bioelectrical activity (BEA) and immunohistochemical effects of the compounds were established. A thorough biological evaluation of the compounds was conducted assessing their in vitro antimicrobial and cytotoxic activity.
resultsAll the newly synthesized compounds exerted drug-like properties, whereby 3-methyl-1-phenylbutan-2-amine
conclusionBased on the experimental results, we outlined 3-methyl-1-phenylbutan-2-amine
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.